Photocure

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Retrieved on: 
Thursday, February 22, 2024
Cevira, Bladder cancer, Congress, HPV, HSIL, Photocure, Mortality, Pharmaceutical industry

Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...

Key Points: 
  • Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...
    Cevira is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix.
  • Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019.
  • Asieris is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
  • All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure to present at four investor conferences in November/December 2023

Retrieved on: 
Monday, November 20, 2023
PHO, CET, Bladder cancer, Conference, Photocure, Cryptocurrency

OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

Key Points: 
  • OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
    The SEB Healthcare Seminar will take place in Stockholm, November 21-23, 2023.
  • David Moskowitz, Photocure's Vice President Investor Relations will present a corporate overview on November 22 at 10:40am CET.
  • The 35th Annual Piper Sandler Healthcare Conference will be held in New York City, November 28-30, 2023.
  • The 14th Annual DNB Nordic Healthcare Conference will be held in Oslo on December 14, 2023.

Photocure to present at four investor conferences in November/December 2023

Retrieved on: 
Monday, November 20, 2023
PHO, CET, Bladder cancer, Conference, Photocure, Cryptocurrency

OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

Key Points: 
  • OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
    The SEB Healthcare Seminar will take place in Stockholm, November 21-23, 2023.
  • David Moskowitz, Photocure's Vice President Investor Relations will present a corporate overview on November 22 at 10:40am CET.
  • The 35th Annual Piper Sandler Healthcare Conference will be held in New York City, November 28-30, 2023.
  • The 14th Annual DNB Nordic Healthcare Conference will be held in Oslo on December 14, 2023.

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Wednesday, November 8, 2023
Cystoscopy, Standard of care, APM, Cevira, Stryker Corporation, BLC, Bladder cancer, FX, Cropping system, EBIT, Bank statement, BD, Growth, FDA citizen petition, CET, CFO, Patient, NOK, Tourism, Pharmaceutical industry, Renewable energy, EBITDA, Photocure

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Wednesday, November 8, 2023
Cystoscopy, Standard of care, APM, Cevira, Stryker Corporation, BLC, Bladder cancer, FX, Cropping system, EBIT, Bank statement, BD, Growth, FDA citizen petition, CET, CFO, Patient, NOK, Tourism, Pharmaceutical industry, Renewable energy, EBITDA, Photocure

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

Photocure ASA: Change of Board Composition

Retrieved on: 
Wednesday, September 27, 2023
Chairperson, Photocure, German company law, Bladder cancer, Management

OSLO, Norway, Sept. 27, 2023 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

Key Points: 
  • OSLO, Norway, Sept. 27, 2023 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.
  • Dr. Egberts has now resigned from the Board of Directors of Photocure ASA.
  • The current board members of Photocure will constitute the Board of Directors after Dr. Egberts' resignation until the general meeting elects a new Board of Directors.
  • Further, the members of the Board of Directors have, after consultation with the nomination committee, resolved that current board member Dylan Hallerberg will take the position as interim Chairperson of the Board of Directors until such election is made.

Photocure ASA: Change of Board Composition

Retrieved on: 
Wednesday, September 27, 2023
Chairperson, Photocure, German company law, Bladder cancer, Management

OSLO, Norway, Sept. 27, 2023 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

Key Points: 
  • OSLO, Norway, Sept. 27, 2023 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.
  • Dr. Egberts has now resigned from the Board of Directors of Photocure ASA.
  • The current board members of Photocure will constitute the Board of Directors after Dr. Egberts' resignation until the general meeting elects a new Board of Directors.
  • Further, the members of the Board of Directors have, after consultation with the nomination committee, resolved that current board member Dylan Hallerberg will take the position as interim Chairperson of the Board of Directors until such election is made.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.